Digitisation | December 16, 2025
Accenture invests in Ryght AI to revolutionize clinical trials
Ryght AI tackles these hurdles with its AI Site Twin platform
Ryght AI tackles these hurdles with its AI Site Twin platform
This launch is part of the company's strategy to expand its nutraceutical portfolio
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Clinical trial enrollment has long been a bottleneck in drug development
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Subscribe To Our Newsletter & Stay Updated
